Molecular determinants for the activating/blocking actions of the 2H-1,4-benzoxazine derivatives, a class of potassium channel modulators targeting the skeletal muscle KATP channels

Molecular Pharmacology

Volumn 74, Issue 1, 2008, Pages 50-58

  Tricarico, Domenico ^a,b   Mele, Antonietta ^a   Camerino, Giulia Maria ^a   Laghezza, Antonio ^a   Carbonara, Giuseppe ^a   Fracchiolla, Giuseppe ^a   Tortorella, Paolo ^a   Loiodice, Fulvio ^a   Camerino, Diana Conte ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Faculty of Pharmacy   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 2 2 (PHENYL)ETHYL 3 (PYRIDIN 3 YL AMINO) 2H 1,4 BENZOXAZINE; 6 CHLORO 2 BENZYL 3 (PYRIDIN 3 YL AMINO) 2H 1,4 BENZOXAZINE; 6 CHLORO 2 BUTYL 3 (PYRIDIN 3 YL AMINO) 2H 1,4 BENZOXAZINE; 6 CHLORO 2 CYCLOHEXYLMETHYL 3 (PYRIDIN 3 YL AMINO) 2H 1,4 BENZOXAZINE; 6 CHLORO 2 HEXYL 3 (PYRIDIN 3 YL AMINO) 2H 1,4 BENZOXAZINE; 6 CHLORO 2 ISOBUTYL 3 (PYRIDIN 3 YL AMINO) 2H 1,4 BENZOXAZINE; 6 CHLORO 2 ISOPROPYL 3 (PYRIDIN 3 YL AMINO) 2H 1,4 BENZOXAZINE; 6 CHLORO 2 PHENYL 3 (PYRIDIN 3 YL AMINO) 2H 1,4 BENZOXAZINE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BENZOXAZINE DERIVATIVE; CROMAKALIM; GLIBENCLAMIDE; POTASSIUM CHANNEL AFFECTING AGENT; TOLBUTAMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; SUBSTITUTION REACTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; BENZOXAZINES; CROMAKALIM; GLYBURIDE; MALE; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MUSCLE, SKELETAL; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; RATS; RATS, WISTAR;

EID: 45749095399     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.046615     Document Type: Article

References (27)

1. + channel channel/enzyme multimer: metabolic gating in the heart. J Mol Cell Cardiol 38:895-905.
2. Allard B and Lazdunski M (1992) Nucleotides diphosphates activate the ATP-sensitive potassium channels in mouse skeletal muscle. Pflugers Arch 422:185-192.
3. Andersson KE (1992) Clinical pharmacology of potassium channel openers. Pharmacol Toxicol 70:244-254.
4. Bienengraeber M, Alexey E, Alekseev M, Abraham R, Carrasco AJ, Moreau C, Vivaudou M, Dzeja PP, and Terzic A (2000) ATPase activity of the sulfonylurea receptor: a catalytic function for the KATP channel complex. FASEB J 14:1943-1952.
5. Camerino DC, Tricarico D, and Desaphy JF (2007) Ion channel pharmacology. Neurotherapeutics 4:184-198.
6. ATP channel openers. Curr Top Med Chem 6:1049-1068.
7. 2+ release and force development during fatigue in vitro. J Physiol 582:843-857.
8. Flechtner I, De Lonlay P, and Polak M (2006) Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences. Diabetes Metab 32:569-580.
9. Haider S, Syma Khalid S, Tucker SJ, Ashcroft FM, and Sansom MSP (2007) Molecular dynamics simulations of inwardly rectifying (Kir) potassium channels: a comparative study. Biochemistry 46:3643-3652.
10. Jahangir A and Terzic A (2005) KATP channel therapeutics at the bedside. J Mol Cell Cardiol 39:99-112.
11. + channels in neonatal diabetes. Implications for pharmacogenomic therapy. Diabetes 54:2645-2654.
12. Links TP, Smit AJ, and Reitsma WD (1995) Potassium channel modulation: effect of pinacidil on insulin release in healthy volunteers. J Clin Pharmacol 35:291-294.
13. Longman SD and Hamilton TC (1992) Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential. Med Res Rev 12:73-148.
14. Lu T, Hong M, and Lee H (2005) Molecular determinants of cardiac KATP channel activation by epoxyeicosatrienoic acids. J Biol Chem 280:19097-19104.
15. Mannhold R (2004) KATP channel structure-activity relationships and therapeutic potential. Med Res Rev 24:213-266.
16. Nichols CG (2006) KATP channels as molecular sensors of cellular metabolism. Nature 440:470-476.
17. + channel openers suppress myotonic activity of human skeletal muscle in vitro. Eur J Pharmacol 186:125-128.
18. Rolland JF, Tricarico D, Laghezza A, Loiodice F, Tortorella V, and Camerino DC (2006) A new benzoxazine compound blocks KATP channels in pancreatic β cells: molecular basis for tissue selectivity in vitro and hypoglycaemic action in vivo. Br J Pharmacol 149:870-879.
19. Rovati GE and Nicosia S (1994) Lower efficacy: interaction with an inhibitory receptor or partial agonism? Trends Pharmacol Sci 15:140-144.
20. 2+. Br J Pharmacol 139:368-380.
21. Saitoh Y (2005) Drugs to facilitate recovery of neuromuscular blockade and muscle strength. J Anesth 19:302-308.
22. + channels in pig urethral myocytes. Br J Pharmacol 133:154-164.
23. Tricarico D, Barbieri M, Laghezza A, Tortorella P, Loiodice F, and Camerino DC (2003) Dualistic actions of cromakalim and new potent 2H-1,4-benzoxazine derivatives on the native skeletal muscle KATP channel. Br J Pharmacol 139:255-262.
24. +-deficient rats. FASEB J 18:760-761.
25. + channels determine their muscletype-dependent biophysical and pharmacological properties. Proc Natl Acad Sci U S A 103:1118-1123.
26. +-depleted rat, an animal model of hypokalemic periodic paralysis. Mol Pharmacol 54:197-206.
27. + channels in patients with hypokalemic periodic paralysis. J Clin Invest 103:675-682.